Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

European Journal of Health Economics

Volumn 15, Issue SUPPL. 1, 2014, Pages

  Gulácsi, László ^a   Rencz, Fanni ^a,b   Péntek, Márta ^a,c   Brodszky, Valentin ^a   Lopert, Ruth ^d,e   Hevér, Noémi V ^a   Baji, Petra ^a  

^a Institute of Entrepreneurship and Innovation   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Pest Megyei Flor Ferenc Korhaz   (Hungary)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e LW Health Policy Consulting   (Australia)

Author keywords

Biologicals; Central and eastern europe; Cost utility; HTA; Inflammatory conditions; Reimbursement

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BULGARIA; CONVENIENCE SAMPLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CZECH REPUBLIC; HUNGARY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; POLAND; PRIORITY JOURNAL; PURCHASING; PURCHASING POWER PARITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RHEUMATOID ARTHRITIS; ROMANIA; SLOVAKIA; COST BENEFIT ANALYSIS; ECONOMICS; EUROPE; HUMAN; ORGANIZATION AND MANAGEMENT; STATISTICAL MODEL;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; COST-BENEFIT ANALYSIS; EUROPE; HUMANS; IMMUNOGLOBULIN G; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, TUMOR NECROSIS FACTOR; REIMBURSEMENT MECHANISMS;

EID: 84905719350     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0591-7     Document Type: Article

References (37)

1. Gulácsi, L., Rotar, A.M., Niewada, M., Löblová, O., Rencz F., Petrova, G., Boncz, I., Klazinga, N.S.: Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. Eur. J. Health Econ. This Supplement (2014). doi:10.1007/s10198-014-0590-8
2. Lopert, R., Lang, D.L., Hill, S.R., Henry, D.A.: Differential pricing of drugs: a role for cost-effectiveness analysis? Lancet 359, 2105-2107 (2002)
3. Lopert, R., Ruiz, F., Chalkidou, K.: Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania. Health Policy 112(3), 202-208 (2013)
4. Drummond, M., Barbieri, M., Cook, J., Glick, H.A., Lis, J., Malik, F., Reed, S.D., Rutten, F., Sculpher, M., Severens, J.: Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 12(4), 409-418 (2009)
5. Péntek, M. (ed.): Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of rheumatoid arthritis. Budapesti Corvinus Egyetem Egészségü gyi Közgazdaságtan Tanszék, Budapest (2014). ISBN:978-963-503-575-5. Available at 19 Mar 2014. http://hecon.uni-corvinus.hu/ download/konyv/Pentek-Biologicals.in.rheumatoid.arthritis-978-963-503-575-5-24. Febr.2014.pdf
6. Péntek, M.: Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Ankylosing Spondylitis. Budapesti Corvinus Egyetem Egészsé gügyi Közgazdaságtan Tanszék, Budapest (2013). ISBN: 978-963-503-561-8. Available at 19 Mar 2014. http://hecon.uni-corvinus.hu/ download/konyv/Pentek-Biologicals.in.Ankylosing.Spondylitis-978-963-503-561-8- 16.Dec.2013.pdf
7. Brodszky, V. (ed.): Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of psoriatic arthritis. Budapesti Corvinus Egyetem Egészségü gyi Közgazdaságtan Tanszék, Budapest (2014). ISBN:978-963-503-574-8. Available at 19 Mar 2014. http://hecon.uni-corvinus.hu/ download/konyv/Brodszky-biologicals.in.Psoriatic.Arthritis-978-963-503-574-8-24. February.2014.pdf
8. Baji, P. (ed.): Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of adult Crohn's disease. Budapesti Corvinus Egyetem Egészségügyi Közgazdaságtan Tanszék, Budapest (2013). ISBN:978-963-503- 558-8. Available at 19 Mar 2014. http://hecon.uni-corvinus.hu/download/konyv/ Baji-Biologicals.in.Crohns.Disease-978-963-503-558-8-28.Nov.2013.pdf
9. Gulácsi, L.: Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of adult Ulcerative Colitis. Budapesti Corvinus Egyetem Egészsé gügyi Közgazdaságtan Tanszék, Budapest (2013). ISBN: 978-963-503-557-1. Available at 19 Mar 2014. http://hecon.uni-corvinus.hu/ download/konyv/Gulacsi-Biologicals.in.Ulcerative.Colitis-978-963-503-557-1-28. Nov.2013.pdf
10. Brodszky, V.: Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Psoriasis. Budapesti Corvinus Egyetem Egészségügyi Közgazdaságtan Tanszék, Budapest (2013). ISBN: 978-963-503-562-5. Available at 19 Mar 2014. http://hecon.unicorvinus.hu/ download/konyv/Brodszky-Biologicals.in.Psoriasis-978-963-503-562-5-16.Dec.2013. pdf
11. Péntek, M., Kobelt, G., Czirják, L., Szekanecz, Z., Poór, G., Rojkovich, B., Polgár, A., Genti, G., Kiss, C.G., Brodszky, V., Májer, I., Gulácsi, L.: Costs of rheumatoid arthritis in Hungary. J. Rheumatol. 34(6), 1437 (2007)
12. Brodszky, V., Bálint, P., Géher, P., Hodinka, L., Horváth, G., Koó, É., Péntek, M., Polgár, A., Seszták, M., Szántó, S., Ujfalussy, I., Gulácsi, L.: Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol. Int. 30(2), 199-205 (2009)
13. Brodszky, V., Orlewska, E., Péntek, M., Kárpáti, K., Skoupá, J., Gulácsi, L.: Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. Med. Sci. Monit. 16(1), SR1-SR5 (2010)
14. Brennan, A., Bansback, N., Reynolds, A., Conway, P.: Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 43(1), 62-72 (2004)
15. Barbieri, M., Wong, J.B., Drummond, M.: The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK. Pharmacoeconomics. 23(6), 607-18 (2005)
16. Chen, Y.F., Jobanputra, P., Barton, P., Jowett, S., Bryan, S., Clark, W., Fry-Smith, A., Burls A.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 10(42), iii-iv, xi-xiii, 1-229 (2006)
17. Kobelt, G., Sobocki, P., Sieper, J., Braun, J.: Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int. J. Technol. Assess. Health Care 23, 368-375 (2007)
18. Ara, R.M., Reynolds, A.V., Conway, P.: The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology (Oxford) 46, 1338-1344 (2007)
19. Botteman, M.F., Hay, J.W., Luo, M.P., Curry, A.S., Wong, R.L., van Hout, B.A.: Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford) 46(8), 1320-1328 (2007)
20. Riemsma, R., Joore, M., Van Asselt, T., Armstrong, N., Misso, K., Manning, N., Tomini, F., Kleijnen, J.: Golimumab for the treatment of ankylosing spondylitis: a single technology appraisal. Kleijnen Systematic Reviews Ltd., York (2011)
21. Bravo Vergel, Y., Hawkins, N.S., Claxton, K., Asseburg, C., Palmer, S., Woolacott, N., Bruce, I.N., Sculpher, M.J.: The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 46, 1729-1735 (2007)
22. Bojke, L., Epstein, D., Craig, D., Rodgers, M., Woolacott, N., Yang, H., Sculpher, M.: Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis. Rheumatology 50(Suppl 4), iv39-iv47 (2011)
23. Yang, H., Craig, D., Epstein, D., Bojke, L., Light, K., Bruce, I.N., Sculpher, M., Woolacott, N.: Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics 30(4), 257-270 (2012)
24. Lindsay, J., Punekar, Y.S., Morris, J., Chung-Faye, G.: Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults. Aliment. Pharmacol. Ther. 28, 76-87 (2008)
25. Bodger, K., Kikuchi, T., Hughes, D.: Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther. 30, 265-274 (2009)
26. Loftus Jr, E.V., Johnson, S.J., Yu, A.P., Wu, E.Q., Chao, J., Mulani, P.M.: Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 21, 1302-1309 (2009)
27. Hyde, C., Bryan, S., Juarez-Garcia, A., Andronis, L., Fry-Smith, A.: Evidence review group report commissioned by the NHS R&D HTA programme on behalf of NICE infliximab for ulcerative colitis. West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, University of Birmingham (2007)
28. Sizto, S., Bansback, N., Feldman, S.R., Willian, M.K., Anis, A.H.: Economic evaluation of systemic therapies for moderate to severe psoriasis. Br. J. Dermatol. 160(6), 1264-1272 (2009)
29. Gaujoux-Viala, C., Fautrel, B.: Cost effectiveness of therapeutic interventions in ankylosis spondylitis. Pharmacoeconomics 30(12), 1145-1156 (2012)
30. de Pouvourville, G., Ulmann, P., Nixon, J., Boulenger, S., Glanville, J., Drummond, M.: The diffusion of health economics knowledge in Europe : the EURONHEED (European Network of Health Economics Evaluation Database) project. Pharmacoeconomics 23 (2), 113-120 (2005)
31. Knies, S.: Transparency of transferability: diagnosing international aspects of economic evaluations of health care technologies. Universitaire Pers, Maastricht (2011)
32. Adapting existing HTAs from one country into other settings. EUnetHTA Adaptation Toolkit: Version 5. EUnetHTA (2011)
33. Reinhold, T., Brüggenjürgen, B., Schlander, M., Rosenfeld, S., Hessel, F., Willich, S.N.: Economic analysis based on multinational studies: methods for adapting findings to national contexts. J. Publ. Health. 18(4), 327-335 (2005)
34. Nixon, J., Rice, S., Drummond, M., Boulenger, S., Ulmann, P., de Pouvourville, G.: Guidelines for completing the EURONHEED transferability information checklists. Eur. J. Health Econ. 10(2), 157-165 (2008)
35. Gulácsi, L., Orlewska, E., Péntek, M.: Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. Eur. J. Health Econ. 13(5), 525-531 (2012)
36. Boncz, I., Nagy, J., Sebestyen, A., Korosi, L.: Financing of health care services in Hungary. Eur. J. Health Econ. 5(3), 252-258 (2004)
37. Boncz, I., Sebestyen, A.: Financial deficits in the health services of the UK and Hungary. Lancet 368 (9539), 917-918 (2006)